Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors

- Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy - - Rate of eligible MAGE-A4 expression was 67% for synovial sarcoma, and ranged from 20%-35% for squamous cell lung, blad